- Home
- ECOR vs APLT Comparison
ECOR vs APLT Comparison
Compare ECOR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- APLT
- Stock Information
- Founded
- ECOR 2005
- APLT 2016
- Country
- ECOR United States
- APLT United States
- Employees
- ECOR N/A
- APLT N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- APLT Health Care
- Exchange
- ECOR Nasdaq
- APLT Nasdaq
- Market Cap
- ECOR 40.1M
- APLT 37.5M
- IPO Year
- ECOR 2018
- APLT 2019
- Fundamental
- Price
- ECOR $6.02
- APLT $0.33
- Analyst Decision
- ECOR Strong Buy
- APLT Buy
- Analyst Count
- ECOR 2
- APLT 7
- Target Price
- ECOR $25.50
- APLT $6.10
- AVG Volume (30 Days)
- ECOR 130.4K
- APLT 2.3M
- Earning Date
- ECOR 05-07-2025
- APLT 04-14-2025
- Dividend Yield
- ECOR N/A
- APLT N/A
- EPS Growth
- ECOR N/A
- APLT N/A
- EPS
- ECOR N/A
- APLT N/A
- Revenue
- ECOR $25,182,000.00
- APLT $455,000.00
- Revenue This Year
- ECOR $32.20
- APLT $3,031.87
- Revenue Next Year
- ECOR $46.27
- APLT $312.01
- P/E Ratio
- ECOR N/A
- APLT N/A
- Revenue Growth
- ECOR 57.09
- APLT N/A
- 52 Week Low
- ECOR $5.02
- APLT $0.30
- 52 Week High
- ECOR $19.49
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ECOR 33.07
- APLT 36.05
- Support Level
- ECOR $5.20
- APLT $0.30
- Resistance Level
- ECOR $6.47
- APLT $0.38
- Average True Range (ATR)
- ECOR 0.71
- APLT 0.05
- MACD
- ECOR 0.33
- APLT -0.00
- Stochastic Oscillator
- ECOR 49.26
- APLT 17.19
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.